Carcinoma, Ovarian Epithelial: all 1,619 studies
Page 9 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)TerminatedNCT03891576Phase 2
- Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian CancerCompletedNCT03881683Not applicable
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsCompletedNCT03872947Phase 1
- Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian CancerTerminatedNCT03858166Phase 4
- A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsCompletedNCT03849469Phase 1
- The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical SignificanceStatus unknownNCT03846856
- Clinical Validation of the InterVenn Ovarian CAncer Liquid BiopsyCompletedNCT03837327
- Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsStatus unknownNCT03827837Phase 2
- Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian CancerStatus unknownNCT03818282Phase 2
- The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian CancerStatus unknownNCT03814447Early Phase 1
- 18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer (PET HOC)CompletedNCT03811899Not applicable
- Imaging Study in Advanced Ovarian CancerStatus unknownNCT03808792
- Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3
- NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)CompletedNCT03804866Phase 2
- MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian CancerStatus unknownNCT03799913Early Phase 1
- Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian CancerStatus unknownNCT03794778Phase 4
- A Phase I Study of SOR-C13 in Patients With Advanced Solid TumorsCompletedNCT03784677Phase 1
- Continued Access to RXDX-105CompletedNCT03784378Phase 1
- A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.Status unknownNCT03763123Phase 1
- TAK-659 and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT03756818Phase 1
- Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian CancerCompletedNCT03754569Not applicable
- NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.CompletedNCT03752216Phase 4
- A Multi-omics Study of Epithelial Ovarian CancerStatus unknownNCT03742856
- Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian CancerCompletedNCT03742713Phase 2
- A Genomic Analysis of Evolution of Epithelia Ovarian TumorsStatus unknownNCT03742388
- Long-acting G-CSF for Febrile NeutropeniaStatus unknownNCT03740464Phase 3
- Non-coding RNA in the Exosome of the Epithelia Ovarian CancerStatus unknownNCT03738319
- Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerWithdrawnNCT03735589Phase 1/2
- Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian CancerStatus unknownNCT03717610Not applicable
- A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerStatus unknownNCT03709316Phase 3
- Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer PatientStatus unknownNCT03705156Phase 3
- An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Status unknownNCT03699449Phase 2
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1
- Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal CancerStatus unknownNCT03693248Phase 3
- Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian CancerStatus unknownNCT03692637Early Phase 1
- Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03691376Phase 1
- Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian CancerActive, not recruitingNCT03691012
- A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.CompletedNCT03681548Phase 1
- DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian CancerCompletedNCT03657966Phase 2
- Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian CancerCompletedNCT03656809
- Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT03639246Phase 1
- Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast CancerWithdrawnNCT03634150Phase 1/2
- Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian CancerWithdrawnNCT03632798Phase 3
- Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO GuidelinesTerminatedNCT03622931Phase 2
- Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian CancerCompletedNCT03622385
- Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian CancerStatus unknownNCT03618706Phase 2
- Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune RepertoireActive, not recruitingNCT03614689
- Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian CancerStatus unknownNCT03611179Phase 2
- Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal MesotheliomaTerminatedNCT03608618Phase 1
- Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant ChemotherapyWithdrawnNCT03607955Phase 1
- Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian CancerCompletedNCT03596281Phase 1
- Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian CancerTerminatedNCT03587129Phase 2
- SEntine Lymph Node in earLY Ovarian Cancer (SELLY)CompletedNCT03563781Not applicable
- Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial CancerCompletedNCT03562897Phase 2
- Open Label Immunotherapy Trial for Ovarian CancerStatus unknownNCT03556566Phase 2
- The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian CancerCompletedNCT03551171Phase 1
- Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard ChemotherapyStatus unknownNCT03547375Phase 2
- Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian CancerStatus unknownNCT03542669Phase 1
- Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma PatientsCompletedNCT03539406Phase 1
- Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian CancerStatus unknownNCT03539328Phase 2
- Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and NeurologyStatus unknownNCT03526809
- Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive SurgeryCompletedNCT03519165Not applicable
- A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian CancerCompletedNCT03509636Phase 1
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
- Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)CompletedNCT03505307
- Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant ChemotherapyCompletedNCT03491033
- Natera Ovarian Cancer Detection AssayTerminatedNCT03485651
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian CarcinomaCompletedNCT03470805Phase 2
- Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.Status unknownNCT03467178Phase 2
- Sentinel Lymph Node in Early Ovarian CancerCompletedNCT03452982Phase 2
- Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian CancerStatus unknownNCT03448354Not applicable
- An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian CancerStatus unknownNCT03446495
- Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerCompletedNCT03430518Phase 1
- A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerWithdrawnNCT03400306Phase 1
- Clinical Impact of Dedicated MR Staging of Ovarian CancerStatus unknownNCT03399344Not applicable
- A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)CompletedNCT03398655Phase 3
- Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)Active, not recruitingNCT03393884Phase 1/2
- A Study of Apatinib Treatment in for Advanced Ovarian CancerStatus unknownNCT03393507Phase 2
- IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOCCompletedNCT03378297Early Phase 1
- Debulking Surgery in Ovarian CancerCompletedNCT03378128Not applicable
- Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive SurgeryStatus unknownNCT03373058Phase 3
- Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian CancerStatus unknownNCT03371693Phase 3
- The Treatment Preferences of Women Diagnosed With Ovarian CancerCompletedNCT03367260
- Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian CancerCompletedNCT03367182
- BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
- Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerCompletedNCT03353831Phase 3
- Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.Status unknownNCT03349463Phase 4
- Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2
- Self-Advocacy Serious Game in Advanced CancerCompletedNCT03339765Not applicable
- Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian CancerStatus unknownNCT03335241Phase 2
- Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal CancerCompletedNCT03332576Phase 1
- Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer PatientsStatus unknownNCT03321188Phase 2
- Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian CarcinomaStatus unknownNCT03302884Not applicable
- Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT03298074Phase 2
- Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian CancerCompletedNCT03297489Early Phase 1
- Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1
- Risk-Reducing Surgeries for Hereditary Ovarian CancerStatus unknownNCT03294343Not applicable
- A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedNCT03292172Phase 1
- A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian CancerWithdrawnNCT03281681Phase 1/2
- Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer PatientsStatus unknownNCT03278717Phase 3